Literature DB >> 17550756

Current management strategies for ovarian cancer.

Giovanni D Aletti1, Mary M Gallenberg, William A Cliby, Aminah Jatoi, Lynn C Hartmann.   

Abstract

Epithelial ovarian cancer originates in the layer of cells that covers the surface of the ovaries. The disease spreads readily throughout the peritoneal cavity and to the lymphatics, often before causing symptoms. Of the cancers unique to women, ovarian cancer has the highest mortality rate. Most women are diagnosed as having advanced stage disease, and efforts to develop new screening approaches for ovarian cancer are a high priority. Optimal treatment of ovarian cancer begins with optimal cytoreductive surgery followed by combination chemotherapy. Ovarian cancer, even in advanced stages, is sensitive to a variety of chemotherapeutics. Although improved chemotherapy has increased 5-year survival rates, overall survival gains have been limited because of our inability to eradicate all disease. Technologic advances that allow us to examine the molecular machinery that drives ovarian cancer cells have helped to identify numerous therapeutic targets within these cells. In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17550756     DOI: 10.4065/82.6.751

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  81 in total

1.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Authors:  Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode
Journal:  Cancer Immunol Immunother       Date:  2015-08-23       Impact factor: 6.968

2.  Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Authors:  Perry T Yin; Shreyas Shah; Nicholas J Pasquale; Olga B Garbuzenko; Tamara Minko; Ki-Bum Lee
Journal:  Biomaterials       Date:  2015-11-12       Impact factor: 12.479

3.  Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.

Authors:  Mengzhen Zhang; Liwei Xu; Xiaoling Wang; Beibei Sun; Juan Ding
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

4.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Authors:  Priya Samuel; Ryan Charles Pink; Daniel Paul Caley; James Michael Stevenson Currie; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Tumour Biol       Date:  2015-09-19

5.  Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers.

Authors:  Sharon Manne; Shannon Myers; Melissa Ozga; David Kissane; Debby Kashy; Stephen Rubin; Carolyn Heckman; Norm Rosenblum
Journal:  Gen Hosp Psychiatry       Date:  2013-10-09       Impact factor: 3.238

Review 6.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 8.  Treatment of myeloma: cure vs control.

Authors:  S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

9.  Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer.

Authors:  Weiya Xia; Yongkun Wei; Yi Du; Jinsong Liu; Bin Chang; Yung-Luen Yu; Long-Fei Huo; Stephanie Miller; Mien-Chie Hung
Journal:  Mol Carcinog       Date:  2009-07       Impact factor: 4.784

10.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.